Metabolic Risk Factors and Statin Therapy Impact Liver and Nonliver Outcomes in Chronic Hepatitis B

Overview

In a large US cohort of 52,277 patients with chronic hepatitis B (CHB), metabolic risk factors (MRFs) such as diabetes mellitus (DM), hypertension, hyperlipidemia, and obesity were associated with increased risks of liver and nonliver complications. Statin use was linked to reduced liver outcomes, including hepatocellular carcinoma (HCC) and cirrhosis, particularly among patients with lower metabolic burden.

Background

Chronic hepatitis B is a major cause of liver cirrhosis and hepatocellular carcinoma worldwide. The rising prevalence of metabolic syndrome, comprising diabetes, hypertension, obesity, and dyslipidemia, contributes to liver and systemic complications. Metabolic dysfunction–associated steatotic liver disease (MASLD) is increasingly common and may synergistically worsen CHB outcomes. While diabetes has been identified as a key driver of adverse outcomes, the combined effects of multiple metabolic risk factors on CHB progression remain incompletely understood. Statins, beyond lipid-lowering, may have protective effects against liver fibrosis and cancer.

Data Highlights

Key Findings

• Patients with diabetes and other metabolic risk factors had significantly higher risks of liver outcomes, cardiovascular disease, chronic kidney disease, and extrahepatic cancers compared to those without metabolic risk factors.
• Increasing metabolic burden correlated with greater risk of adverse liver and nonliver outcomes, except in patients with metabolic risk factors but no diabetes.
• Statin use among patients with ≤2 metabolic risk factors was associated with a 15% lower risk of any liver outcome, 35% reduced risk of hepatocellular carcinoma, and 15% lower risk of cirrhosis.
• No significant protective effect of statins was observed in patients with ≥3 metabolic risk factors.
• Diabetes mellitus had the highest impact among metabolic risk factors on adverse outcomes in CHB patients.

Clinical Implications

Clinicians should carefully assess metabolic risk factors in patients with chronic hepatitis B, as higher metabolic burden substantially increases the risk of liver and systemic complications. Statin therapy may offer protective benefits against liver disease progression and hepatocellular carcinoma in patients with lower metabolic burden and should be considered as part of comprehensive management. However, the benefit of statins appears limited in patients with multiple metabolic risk factors, highlighting the need for tailored therapeutic strategies.

Conclusion

Higher metabolic burden, especially diabetes mellitus, significantly elevates the risk of liver and nonliver complications in chronic hepatitis B. Statin use is associated with reduced liver-related outcomes in patients with lower metabolic risk, underscoring the importance of metabolic risk management in this population.

References

1. Chronic Hepatitis B and Metabolic Risk Factors Study, 2024 -- Evaluation of Metabolic Risk Factors and Statin Therapy in Relation to Liver and Nonliver Outcomes in Patients with Chronic Hepatitis B